One of the main problems in sickle cell disease is the decreased bioavailability of nitric
oxide and arginine. This study was designed to assess if treating sickle cell disease
patients with L-arginine would improve pulmonary arterial pressure and other aspects.
Phase:
Phase 3
Details
Lead Sponsor:
Hospital de Clinicas de Porto Alegre
Collaborators:
Ajinomoto Interamericana Indústria e Comércio Ltda. (donation of L-arginine) Associação de Amigos da Hematologia (HEMOAMIGOS) Fundo de Incentivo à Pesquisa do Hospital de Clinicas de Porto Alegre (FIPE)